The FDA IND clearance supports the initiation of RiboX's Phase 1 clinical trial evaluating targeted LNP-delivered circular RNA-based in vivo CAR-T therapy for autoimmune cytopenias. RXIM002 represents the world's first circular RNA-based in vivo CAR-T therapy achieving FDA IND clearance. RiboX expands its clinical-stage pipeline through its proprietary...
HONG KONG, Jan. 13, 2025 /PRNewswire/ -- Gianna Lullume, an innovative brand committed to improving infant sleep and promoting family well-being, is proud to...
SHANGHAI and NORTH CHICAGO, Ill., Jan. 13, 2025 /PRNewswire/ -- Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group Ltd (HKEX: 2096) and AbbVie Inc....
SHENZHEN, China, Jan. 13, 2025 /PRNewswire/ -- Addentax Group Corp. ("Addentax" or the "Company") (Nasdaq: ATXG), an integrated service provider focusing on garment manufacturing,...
- Preparing for Phase 2 Global Trials of a Ferritin Platform-Based Virus-Like Particle Universal Coronavirus Vaccine
- Based on the Excellent Safety and Immune Response in...
STAMFORD, Conn., Jan. 13, 2025 /PRNewswire/ -- Trillium Flow Technologies ("Trillium"), a portfolio company of First Reserve, and a global designer, manufacturer, and aftermarket...